Literature DB >> 2892475

[Nervous system involvement in HIV1 infections in infants].

M Tardieu1, S Blanche, C Rouzioux, F Veber, A Fischer, C Griscelli.   

Abstract

A prospective survey of 38 HIV1-infected infants has been performed. Thirty-four percent of the patients expressed neurological abnormalities. Three main clinical entities of various intensity have been defined: 8 patients had severe intellectual and motor dysfunctions associated with a bucco-lingual dyspraxia; in 4 patients, the intellectual and motor alterations were less intense but were associated with a severe bucco-lingual dyspraxia; finally one patient had no clinical symptomatology but a chronic lymphocytic meningitis. No opportunistic infection of the CNS was observed. The neurological alterations were correlated in intensity with the immunological dysfunction. CT scans were normal or showed cerebral atrophy in most cases. CSF were normal in 12 cases and a pleiocytosis was observed in one case. However, in 4 of the 6 tested cases, anti-HIV antibodies were detected in CSF.

Entities:  

Mesh:

Year:  1987        PMID: 2892475

Source DB:  PubMed          Journal:  Arch Fr Pediatr        ISSN: 0003-9764


  3 in total

1.  How frequent and how early does the neurological involvement in HIV-positive children occur? Preliminary results of a prospective study.

Authors:  A M Laverda; P Cogo; A Condini; C Cattelan; C Giaquinto; S Cozzani; E Ruga; F Viero; A De Rossi; A Del Mistro
Journal:  Childs Nerv Syst       Date:  1990-11       Impact factor: 1.475

Review 2.  Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment.

Authors:  C Exhenry; D Nadal
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

3.  Stable human immunodeficiency virus encephalopathy in two infants receiving early intravenous gammaglobulin plus antimicrobial prophylaxis.

Authors:  U A Hunziker; D Nadal; J B Jendis; Z Tomasik; J C Wetzel; J Schüpbach; R A Seger
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.